UCB Targets Covidien Unit Over Ritalin Patent
Belgian pharmaceutical giant UCB Inc. on Thursday hit Covidien PLC subsidiary Mallinckrodt Inc. with a patent infringement suit over the rival drugmaker's plan to sell a generic version of Ritalin, UCB's...To view the full article, register now.
Already a subscriber? Click here to view full article